1. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy
- Author
-
Nina Singh, David L. Paterson, Emanuel N. Vergis, Susan Swindells, and Marilyn M. Wagener
- Subjects
Adult ,Male ,medicine.medical_specialty ,Anti-HIV Agents ,HIV Infections ,Hyperlipidemias ,Dermatology ,Gastroenterology ,chemistry.chemical_compound ,High-density lipoprotein ,Pharmacotherapy ,Indinavir ,Internal medicine ,medicine ,Humans ,Protease Inhibitors ,Pharmacology (medical) ,Prospective Studies ,Prospective cohort study ,Triglycerides ,Aged ,business.industry ,Cholesterol ,Cholesterol, HDL ,Public Health, Environmental and Occupational Health ,Cholesterol, LDL ,Middle Aged ,Viral Load ,medicine.disease ,CD4 Lymphocyte Count ,Regimen ,Infectious Diseases ,chemistry ,Immunology ,HIV-1 ,RNA, Viral ,Drug Therapy, Combination ,Female ,lipids (amino acids, peptides, and proteins) ,Lipodystrophy ,business ,Viral load ,medicine.drug - Abstract
Metabolic complications are being increasingly recognized among HIV-infected patients treated with potent combination antiretroviral therapies. We sought to assess the association of dyslipidaemia with adherence to protease inhibitor (PI) therapy and with the markers of clinical response to antiretroviral therapy (CD4 count, HIV RNA viral level) through a prospective, cross-sectional cohort study. Fifty-six HIV-infected patients who were already on, or who were started on PI-containing antiretroviral therapy were monitored for the development of dyslipidaemias. Therapy with PI-containing antiretroviral therapy was significantly associated with elevated serum triglyceride level (>250 mg/dl) (52% vs 8%, P=0.001). Patients with an adherence rate of at least 80% to a PI-containing regimen were significantly more likely to have elevated low density lipoprotein (LDL) cholesterol level as compared to patients with an adherence rate of 800 mg/dl) as compared to patients with an adherence rate of
- Published
- 2001
- Full Text
- View/download PDF